A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a commercial-stage biopharmaceutical company pioneering a transformational approach to treating cancer. Our mission is to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte, or TIL, cell therapies for patients with solid tumor cancers. TIL cell therapies harness the individual immune system’s ability to recognize and destroy diverse cancer cells that are unique to each patient. These individualized therapies are manufactured using centralized, scalable, and proprietary manufacturing processes which rejuvenate and multiply each patient’s polyclonal T cells into the billions. Iovance was founded to build upon the promise of TIL cell therapy initially developed at academic research centers, including the National Cancer Institute, or the NCI.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|
| Revenue | 264M | 264M | - | - | 0 | 0 |
| Net Income | -391M | -391M | -372M | -444M | -124M | -92M |
| EPS | $-1.09 | $-1.09 | $-1.28 | $-1.89 | $-1.27 | $-1.41 |
| Free Cash Flow | -336M | -336M | -364M | -384M | -102M | -80M |
| ROIC | -59.3% | -56.0% | -52.3% | -75.8% | -26.7% | -63.3% |
| Gross Margin | 34.3% | 34.3% | - | - | - | - |
| Debt/Equity | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.07 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -403M | -403M | -395M | -461M | -128M | -93M |
| Operating Margin | -153.1% | -153.1% | - | - | - | - |
| ROE | -56.0% | -55.5% | -52.4% | -76.0% | - | -63.3% |
| Shares Outstanding | 359M | 359M | 291M | 235M | 97M | 65M |
IOVANCE BIOTHERAPEUTICS, INC. passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 34.3%.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) has a 5-year average return on invested capital (ROIC) of -54.8%. This is below average and may indicate limited pricing power.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) has a market capitalization of $1.3B. It is classified as a small-cap stock.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) does not currently pay a regular dividend.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported annual revenue of $264 million in its most recent fiscal year, based on SEC EDGAR filings.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) has a net profit margin of -148.4%. The company is currently unprofitable.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) generated $-336 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported earnings per share (EPS) of $-1.09 in its most recent fiscal year.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) has a return on equity (ROE) of -55.5%. A negative ROE may indicate losses or negative equity.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) has a 5-year average gross margin of 34.3%. This indicates decent pricing power.
The Ledger Terminal provides 13 years of financial data for IOVANCE BIOTHERAPEUTICS, INC. (IOVA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) has a book value per share of $1.95, based on its most recent annual SEC filing.